SINGAPORE, 1 July 2021 – We are excited to announce our new partnership in Indonesia for the distribution of PROFHILO®. Neoasia Singapore is partnering with PT Anugerah Pharmindo Lestari (also known as APL, a member of Zuellig Pharma) to launch PROFHILO® in Indonesia. Neoasia had been working closely with Zuellig Pharma in Singapore, Malaysia and Vietnam for the past two decades. We are confident that Zuellig Pharma has the best-in-class capabilities to ensure PROFHILO® is transported in pharmaceutical cold-chain logistic throughout the entire delivery process.
With the assistance from APL, we have formed our first commercial team in Indonesia, to ensure timely information, update and support are given to all our customers.
PROFHILO® was first launched in Europe in 2015. Subsequently Neoasia launched it in Singapore in Q4-2019. With the experience we had garnered, we are positive that this game changer would be the long awaited “injectable skincare” that everyone is waiting for.
“Based on the uptake of PROFHILO® in Europe, Singapore, Malaysia and Vietnam, we are confident that the doctors and patients in Indonesia would love the product as much as we do. It is our mission to deliver the best clinically proven and highest efficacy products to our partner doctors in Asia,” said Mr Chen Heng Hui, Neoasia CEO.
A screen grab of the Welcoming Meeting with our team in Indonesia and APL.
Neoasia is committed to deliver our best to all the customers in Indonesia and make this launch a success. We would like the take this opportunity to thank the team at APL for all their support in the preparation for this launch.